| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net cash provided by (used in) operating activities | -14,023 | -10,291 |
| Purchase of property and equipment | 1,235 | 737 |
| Amounts funded in respect of employee rights upon retirement, net | 19 | 13 |
| Net cash provided by (used in) investing activities | -1,254 | -750 |
| Proceeds from issuance of common stock under the sales agreement, net | 6,812 | 6,812 |
| Exercise of warrants and options | 2,368 | 2,368 |
| Net cash provided by (used in) financing activities | 9,180 | 9,180 |
| Effect of exchange rate changes on cash and cash equivalents | -16 | -4 |
| Net increase (decrease) in cash and cash equivalents | -6,113 | -1,865 |
| Cash and cash equivalents at beginning of period | 19,760 | - |
| Cash and cash equivalents at end of period | 13,647 | - |
Protalix BioTherapeutics, Inc. (PLX)
Protalix BioTherapeutics, Inc. (PLX)